Pharmaceutical News

RSS

GCP could help lengthen life expectancy of certain prostate cancer patients

A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.

21 Feb 2013

Veterans diagnosed with reflux issues often start on high doses of drugs, rarely stop therapy

U.S. veterans diagnosed with gastroesophageal reflux disease (GERD) are frequently prescribed doses of proton pump inhibitors (PPIs), such as omeprazole (commonly known by brand names such as Prilosec), that are much higher than recommended --- and they are kept on the drug far too long, according to a new Northwestern Medicine- study.

21 Feb 2013

Calcium supplement intake may increase risk of death from heart disease in men

In a new study from the National Institutes of Health, startling results showed that men who took calcium supplements were more apt to die of heart disease than those who didn't get extra calcium in supplement form.

20 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Child cancer survival rate progress threatened by lack of new drug development

Remarkable improvements in survival from childhood cancer have taken place in high- income countries over the past 50 years, but further progress is being threatened by increasingly strict research regulations and insufficient development of new drugs, according to a major new Lancet Oncology Series on improving cancer care for children and young people.

20 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

Novartis CEO upbeat in the midst of market challenges

One of the worst flu seasons in decades is finally showing signs of abating. But health care companies and individuals are still absorbing higher costs as the president's health care legislation begins to take effect. The fees and taxes related to Obamacare take effect this year, while the rest will be implemented in the coming two years.

20 Feb 2013

Ipsen, Inspiration Biopharmaceuticals sell IB1001 hemophilia B product to Cangene

Inspiration Biopharmaceuticals and Ipsen today announced the closing of the sale of the proprietary hemophilia B product, IB1001 (recombinant FIX), to Cangene Corporation.

20 Feb 2013

Immature malaria parasites more resistant to treatment with artemisinin

New research has revealed that immature malaria parasites are more resistant to treatment with key antimalarial drugs than older parasites, a finding that could lead to more effective treatments for a disease that kills one person every minute and is developing resistance to drugs at an alarming rate.

20 Feb 2013

SanMedica’s SeroVital-hgh could revolutionize both anti-aging and weight-loss industries

While the Obesity Society's prestigious 30th Annual Scientific Meeting is the venue for some of the most cutting-edge obesity research in the world, at this year's conference the main highlight wasn't weight loss, but was instead — believe it or not — anti-aging. Research presented by a group of highly renowned scientists revealed an oral compound that experts are predicting could completely revolutionize both the anti-aging and weight-loss industries.

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Scientists create new strain of polio to protect vaccine factory workers

"Scientists have created new strains of polio intended to protect workers in factories that make polio vaccine," the New York Times reports.

20 Feb 2013

Gilead to resolve Viread patent litigation case with Teva

Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

20 Feb 2013

Study evaluates effectiveness of H1N1 vaccine in pregnant women against adverse infant outcomes

Pregnant women who received the H1N1 influenza vaccine during the 2009 pandemic were less likely to have premature babies, and their babies weighed more on average.

20 Feb 2013

Meloxicam recognizes and treats osteoarthritis in cats

Scientists at the University of Montreal's Quebec Research Group in Animal Pharmacology have found a way to recognize and treat osteoarthritis in cats - a condition that the owner might not notice and that can make even petting painful.

20 Feb 2013

New coronavirus could potentially be treated with immunotherapy

The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published on February 19 in mBio-, the online open-access journal of the American Society for Microbiology.

20 Feb 2013

SARS-linked virus well adapted to infect humans, could be treated with drugs to boost immune system, study shows

"A new virus that emerged in the Middle East last year and has killed five people is well adapted to infecting humans but could potentially be treated with drugs that boost the immune system, scientists said on Tuesday," Reuters reports, noting, "The virus, called novel coronavirus or NCoV, is from the same family as the common cold and as SARS, or Severe Acute Respiratory Syndrome."

19 Feb 2013

EMA designates Osiris as Orphan Drug title holder for Prochymal

Osiris Therapeutics, Inc., the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal (remestemcel-L).

19 Feb 2013

Sucampo's RESCULA 0.15% now available by prescription across the U.S.

Sucampo Pharmaceuticals, Inc. today announced that RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% is now available by prescription across the United States. The U.S. Food and Drug Administration (FDA) approved a sNDA for RESCULA for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension on December 7, 2012.

19 Feb 2013